Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.
台灣2型糖尿病患者中虛弱對GLP-1受體激動劑與SGLT2抑制劑效果及安全性的影響:一項回顧性全國性縱向研究。
Lancet Healthy Longev 2024-09-16
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
GLP-1 受體激動劑與代謝功能障礙相關脂肪肝疾病患者肝硬化及相關併發症的風險。
JAMA Intern Med 2024-09-16
General practitioner and nurse experiences of type 2 diabetes management and prescribing in primary care: a qualitative review following the introduction of funded SGLT2i/GLP1RA medications in Aotearoa New Zealand.
初級醫療中全科醫生和護理人員對第二型糖尿病管理和處方的經驗:在新西蘭 Aotearoa 引入資助的 SGLT2i/GLP1RA 藥物後的質性回顧。
Prim Health Care Res Dev 2024-09-16
Selective Agonism of Liver and Gut FXR Prevents Cholestasis and Intestinal Atrophy in Parenterally Fed Neonatal Pigs.
選擇性激動肝臟和腸道 FXR 可防止靜脈營養餵養的新生豬膽汁淤積和腸道萎縮。
bioRxiv 2024-09-16
Lifestyle Profiling Using Wearables and Prediction of Glucose Metabolism in Individuals with Normoglycemia or Prediabetes.
使用可穿戴設備進行生活方式分析及預測正常血糖或前期糖尿病個體的葡萄糖代謝。
medRxiv 2024-09-16
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.
GLP-1 單一、雙重及三重受體激動劑在治療第二型糖尿病和肥胖症中的應用:敘述性回顧。
EClinicalMedicine 2024-09-16